Resources

Microfluidic affinity profiling reveals a broad range of target affinities for anti-SARS-CoV-2 antibodies in plasma of Covid survivors

Authors: Matthias M. Schneider, Marc Emmenegger, Catherine K. Xu, Itzel Condado Morales, Priscilla Turelli, Manuela R. Zimmermann, Beat M. Frey, Sebastian Fiedler, Viola Denninger, Georg Meisl, Vasilis Kosmoliaptsis, Heike Fiegler, Didier Trono, Tuomas P. J. Knowles, and Adriano Aguzzi

medRxiv2020, 20196907. DOI: 10.1101/2020.09.20.20196907

 

Abstract

The clinical outcome of SARS-CoV-2 infections can range from asymptomatic to lethal, and is thought to be crucially shaped by the quality of the immune response which includes antibody titres and affinity for their targets. Using Microfluidic Antibody Affinity Profiling (MAAP), Schneider et al. determined the aggregate affinities and concentrations of anti-SARS-CoV-2 antibodies in plasma samples of 42 seropositive individuals, 23 of whom were confirmed to be SARS-CoV-2-positive by PCR testing. They found that dissociation constants (KD) of anti-RBD antibodies spanned more than two orders of magnitude from 80 pM to 25 nM, despite having similar antibody concentrations. The tested individuals showed progressively higher antibody concentrations but constant KD values, suggesting that affinities did not mature over time. 33 sera showed affinities higher than that of the CoV2 spike for its ACE2 receptor.

Accordingly, addition of seropositive plasma to pre-formed spike-ACE2 receptor complexes led to their dissociation. Finally, they observed that the RBD of HKU1, OC43, and SARS-CoV coronaviruses, but not unrelated control proteins, were able to compete substantially with the RBD of SARS-CoV-2 in solution.

Therefore, the affinity of total plasma immunoglobulins to SARS-CoV-2 is an indicator of the quality of the immune response to SARS-CoV-2, and may help select the most efficacious samples for therapeutic plasmapheresis.

READ THE FULL PAPER HERE

 


InstrumentFluidity One-W Serum
Therapeutic area: COVID

Could this support your research?

Get in touch, our applications scientists will be happy to discuss your application requirements with you.

Learn more